Deutsche Bank’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-183,241
| Closed | -$31.5M | – | 4514 |
|
|
2021
Q3 | $31.5M | Sell |
183,241
-5,231
| -3% | -$684K | 0.02% | 742 |
|
|
2021
Q2 | $23.7M | Buy |
188,472
+65,412
| +53% | +$8.25M | 0.01% | 851 |
|
|
2021
Q1 | $16.7M | Buy |
123,060
+26,337
| +27% | +$3.4M | 0.01% | 966 |
|
|
2020
Q4 | $12.4M | Sell |
96,723
-22
| -0% | -$2.58K | 0.01% | 952 |
|
|
2020
Q3 | $10.9M | Sell |
96,745
-13,497
| -12% | -$1.34M | 0.01% | 938 |
|
|
2020
Q2 | $10.5M | Sell |
110,242
-27,614
| -20% | -$2.66M | 0.01% | 957 |
|
|
2020
Q1 | $12.4M | Buy |
137,856
+18,265
| +15% | +$1.42M | 0.01% | 841 |
|
|
2019
Q4 | $6.34M | Buy |
119,591
+2,622
| +2% | +$120K | ﹤0.01% | 1313 |
|
|
2019
Q3 | $4.62M | Sell |
116,969
-10,018
| -8% | -$435K | ﹤0.01% | 1446 |
|
|
2019
Q2 | $5.21M | Buy |
126,987
+9,522
| +8% | +$394K | ﹤0.01% | 1777 |
|
|
2019
Q1 | $5.47M | Sell |
117,465
-39,882
| -25% | -$1.75M | ﹤0.01% | 1815 |
|
|
2018
Q4 | $6.85M | Sell |
157,347
-209,543
| -57% | -$10.5M | ﹤0.01% | 1542 |
|
|
2018
Q3 | $21M | Buy |
366,890
+42,870
| +13% | +$2.11M | 0.01% | 1106 |
|
|
2018
Q2 | $15.7M | Sell |
324,020
-205,399
| -39% | -$7.48M | 0.01% | 1355 |
|
|
2018
Q1 | $20.7M | Sell |
529,419
-4,838
| -0.9% | -$206K | 0.01% | 1095 |
|
|
2017
Q4 | $22.7M | Sell |
534,257
-391,735
| -42% | -$14.7M | 0.01% | 921 |
|
|
2017
Q3 | $34.6M | Buy |
925,992
+536,830
| +138% | +$18.6M | 0.02% | 710 |
|
|
2017
Q2 | $11.8M | Buy |
389,162
+43,226
| +12% | +$1.25M | 0.01% | 1285 |
|
|
2017
Q1 | $9.16M | Buy |
345,936
+64,049
| +23% | +$1.69M | 0.01% | 1316 |
|
|
2016
Q4 | $7.19M | Sell |
281,887
-37,146
| -12% | -$1.18M | 0.01% | 1454 |
|
|
2016
Q3 | $11.5M | Sell |
319,033
-54,214
| -15% | -$1.8M | 0.01% | 1220 |
|
|
2016
Q2 | $12.7M | Buy |
373,247
+62,625
| +20% | +$2.04M | 0.01% | 1166 |
|
|
2016
Q1 | $8.2M | Buy |
310,622
+142,447
| +85% | +$4.14M | 0.01% | 1390 |
|
|
2015
Q4 | $8.2M | Buy |
168,175
+65,580
| +64% | +$2.36M | 0.01% | 1449 |
|
|
2015
Q3 | $2.55M | Sell |
102,595
-12,521
| -11% | -$376K | ﹤0.01% | 2318 |
|
|
2015
Q2 | $3.64M | Buy |
115,116
+17,631
| +18% | +$569K | ﹤0.01% | 2029 |
|
|
2015
Q1 | $3.71M | Buy |
97,485
+10,824
| +12% | +$430K | ﹤0.01% | 2004 |
|
|
2014
Q4 | $3.37M | Sell |
86,661
-8,180
| -9% | -$285K | ﹤0.01% | 2265 |
|
|
2014
Q3 | $2.87M | Buy |
94,841
+35,894
| +61% | +$1.01M | ﹤0.01% | 2244 |
|
|
2014
Q2 | $2M | Buy |
58,947
+55,853
| +1,805% | +$1.87M | ﹤0.01% | 2445 |
|
|
2014
Q1 | $106K | Buy |
3,094
+3,049
| +6,776% | +$138K | ﹤0.01% | 4214 |
|
|
2013
Q4 | $1K | Buy |
+45
| New | +$1.09K | ﹤0.01% | 5324 |
|
Deutsche Bank's XLRN Position: Q4 2021 in Review
Deutsche Bank sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 183,241 shares — an estimated $31.5M sold.
Deutsche Bank first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $34.6M in Q3 2017. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Deutsche Bank reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Deutsche Bank sold 183,241 Acceleron Pharma shares in Q4 2021, an estimated $31.5M.
- Deutsche Bank first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Deutsche Bank's Acceleron Pharma position peaked at $34.6M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Deutsche Bank's 13F filing for Q4 2021, filed 11 Feb 2022.